Edgewise Therapeutics
Maria Mancini is currently the Vice President, Head of Clinical Development Operations at Edgewise Therapeutics. Maria also holds a senior faculty position in Regulatory Affairs at Northeastern University, where Maria teaches graduate-level courses. Maria previously served in various leadership roles at Catabasis Pharmaceuticals, Inc. and Genzyme, with a focus on clinical operations and research. Maria has also taught at MCPHS University and has a strong academic background, holding a Bachelor of Science in Health Science from Merrimack College and a Master's degree in Health Policy from Northeastern University.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.